Oncogenic cancer/testis antigens: prime candidates for immunotherapy
- PMID: 26158218
- PMCID: PMC4599236
- DOI: 10.18632/oncotarget.4694
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Abstract
Recent developments have set the stage for immunotherapy as a supplement to conventional cancer treatment. Consequently, a significant effort is required to further improve efficacy and specificity, particularly the identification of optimal therapeutic targets for clinical testing. Cancer/testis antigens are immunogenic, highly cancer-specific, and frequently expressed in various types of cancer, which make them promising candidate targets for cancer immunotherapy, including cancer vaccination and adoptive T-cell transfer with chimeric T-cell receptors. Our current understanding of tumor immunology and immune escape suggests that targeting oncogenic antigens may be beneficial, meaning that identification of cancer/testis antigens with oncogenic properties is of high priority. Recent work from our lab and others provide evidence that many cancer/testis antigens, in fact, have oncogenic functions, including support of growth, survival and metastasis. This novel insight into the function of cancer/testis antigens has the potential to deliver more effective cancer vaccines. Moreover, immune targeting of oncogenic cancer/testis antigens in combination with conventional cytotoxic therapies or novel immunotherapies such as checkpoint blockade or adoptive transfer, represents a highly synergistic approach with the potential to improve patient survival.
Keywords: cancer/testis antigen; immunotherapy; oncogenesis.
Conflict of interest statement
None
Figures
Similar articles
-
[Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy].Nihon Rinsho. 2012 Dec;70(12):2125-9. Nihon Rinsho. 2012. PMID: 23259384 Review. Japanese.
-
Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188558. doi: 10.1016/j.bbcan.2021.188558. Epub 2021 Apr 29. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33933558 Review.
-
Cancer-testis antigens: potential targets for cancer immunotherapy.Arch Iran Med. 2009 Jul;12(4):395-404. Arch Iran Med. 2009. PMID: 19566358 Review.
-
A novel era of cancer/testis antigen in cancer immunotherapy.Int Immunopharmacol. 2021 Sep;98:107889. doi: 10.1016/j.intimp.2021.107889. Epub 2021 Jun 24. Int Immunopharmacol. 2021. PMID: 34174699 Review.
-
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.Immunol Rev. 2002 Oct;188:22-32. doi: 10.1034/j.1600-065x.2002.18803.x. Immunol Rev. 2002. PMID: 12445278 Review.
Cited by
-
Selective loss of Y chromosomes in lung adenocarcinoma modulates the tumor immune environment through cancer/testis antigens.bioRxiv [Preprint]. 2024 Sep 22:2024.09.19.613876. doi: 10.1101/2024.09.19.613876. bioRxiv. 2024. PMID: 39345481 Free PMC article. Preprint.
-
PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA.Elife. 2024 Sep 20;12:RP88256. doi: 10.7554/eLife.88256. Elife. 2024. PMID: 39302097 Free PMC article.
-
NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clin Transl Med. 2024 Sep;14(9):e70020. doi: 10.1002/ctm2.70020. Clin Transl Med. 2024. PMID: 39275923 Free PMC article. Review.
-
Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma.Genome Med. 2024 Aug 19;16(1):102. doi: 10.1186/s13073-024-01363-y. Genome Med. 2024. PMID: 39160595 Free PMC article.
-
Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer.Mol Ther Oncol. 2024 Jan 26;32(1):200768. doi: 10.1016/j.omton.2024.200768. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596293 Free PMC article. Review.
References
-
- Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, Odunsi K, Altorki NK, Song CJ, Jin BQ, Simpson AJ, Old LJ. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. International journal of cancer Journal international du cancer. 2009;124:2893–2898. - PubMed
-
- dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van Muijen GN, van Kessel AG. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer research. 2000;60:1654–1662. - PubMed
-
- Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, et al. Genome-wide analysis of cancer/testis gene expression. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:20422–20427. - PMC - PubMed
-
- Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, Pfreundschuh M. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. International journal of cancer Journal international du cancer. 1998;78:387–389. - PubMed
-
- Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, Ruiter DJ, van Muijen GN. Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. Melanoma research. 2001;11:451–459. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous